Medica Jadertina, Vol. 52 No. 2, 2022.
Pregledni rad
https://doi.org/10.57140/mj.52.2.6
Possible immunological mechanisms in COVID-19 patients with immune thrombocytopenic purpura
Mohammad Bahadoram
; Thalassemia and hemoglobinopathy research center, Research institute of health, Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran
Ali Saeedi-Boroujeni
; Ahvaz Jundishapur University of medical sciences, Faculty of medicine, Department of immunology, Ahvaz, Iran
Mohammad-Reza Mahmoudian-Sani
; Thalassemia and hemoglobinopathy research center, Research institute of health, Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran
Sažetak
Millions of people around the world were, or are still involved with COVID-19 due to infection with
SARS-CoV-2. In addition to hallmark symptoms, thrombotic problems, lymphopenia, and thrombocytopenia
have also been reported in COVID-19 patients, of which ITP is the most common and occurs in more than
one-third of COVID-19 patients. Hyperinflammation, cytokine storms, and generally immune dysregulation
in a percentage of patients develop the main consequences of diseases such as ALI, ARDS and multiple organ
failure. Some of the important events in the immunopathogenesis of this disease are disruption of T-cell
effector differentiation and the destructive role of Th17 lymphocytes, neutrophil function and inflammatory
macrophages. NLRP3-inflammasome hyperactivity causes serious dysfunction of innate immune cells and,
consequently, T lymphocytes in many inflammatory disorders, most notably in the COVID-19. A closer look
at the immunopathogenesis of ITP and COVID-19 brings us to common ground. The purpose of this study
was to review and summarize the findings of various studies on the immunopathogenesis of ITP and its
possible causes in COVID-19. Finally, enhanced differentiation of Th17 and Th1, the cell death called as
pyroptosis, hyperinflammation and dysfunction of inflammatory neutrophils and macrophages, and NLRP3-
inflammasome hyperactivity are important factors in the development of thrombocytopenia in patients with
COVID-19. Further studies are needed to better understand immunopathogenesis and effective treatments for
ITP, especially in inflammatory disorders
Ključne riječi
COVID-19-SARS-CoV2; inflammasome; immune thrombocytopenic purpura; platelets; immune dysregulation
Hrčak ID:
281508
URI
Datum izdavanja:
25.8.2022.
Posjeta: 466 *